文献速递腹部泌尿生殖CTMR

同时存在的LR-5是否与LR-3或LR-4观察中肝细胞癌发生率更高相关?一项个体参与者数据Meta分析

Is concurrent LR-5 associated with a higher rate of hepatocellular carcinoma in LR-3 or LR-4 observations? An individual participant data meta-analysis.
PubMed 文献 · Abdom Radiol (NY) · 2024-09-27

该个体参与者数据Meta分析纳入29项研究、1456例患者共2591个观察,评估同时存在LR-5是否改变LR-3或LR-4观察代表肝细胞癌的概率。结果显示LR-3伴与不伴同时LR-5的阳性预测值无显著差异(45.4% vs 37.1%,p=0.63),LR-4亦无显著差异(88.6% vs 69.5%,p=0.08),支持现行LI-RADS分类框架。

要点

  • LR-3观察伴同时LR-5的HCC阳性预测值为45.4%,不伴LR-5为37.1%,两者无显著差异(p=0.63)。
  • LR-4观察伴同时LR-5的HCC阳性预测值为88.6%,不伴LR-5为69.5%,两者无显著差异(p=0.08)。
  • 低偏倚风险研究(n=9)的敏感性分析与主分析结果无差异,支持现行LI-RADS分类不因同时存在LR-5而改变LR-3/LR-4归类。

核心结论

  • 同时存在LR-5与LR-3或LR-4观察的HCC阳性预测值差异无统计学显著关联,支持现行LI-RADS框架,即同时存在的LR-5可能不改变LR-3和LR-4观察的分类。

研究设计与样本

  • 个体参与者数据Meta分析,检索2014年1月至2023年2月多个数据库,纳入29项评估CT/MRI使用LI-RADS v2014/2017/2018诊断HCC准确性的研究,共2591个观察、1456例患者(平均年龄59岁,1083例[74%]男性),采用广义线性混合模型以一步法Meta分析合并个体参与者数据估计阳性预测值,偏倚风险采用复合参考标准和QUADAS-2评估。

诊断标准与关键数值

  • LR-3观察伴同时LR-5的HCC阳性预测值为45.4%,不伴LR-5为37.1%,两者差异无统计学显著(p=0.63)。
  • LR-4观察伴同时LR-5的HCC阳性预测值为88.6%,不伴LR-5为69.5%,两者差异无统计学显著(p=0.08)。
  • 低偏倚风险研究(n=9)的敏感性分析与主分析结果无差异。

临床应用与阅片要点

  • 作者结论支持现行LI-RADS分类框架,即同时存在的LR-5可能不改变LR-3和LR-4观察的分类。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: The Liver Imaging Reporting and Data System (LI-RADS) does not consider factors extrinsic to the observation of interest, such as concurrent LR-5 observations.

PURPOSE: To evaluate whether the presence of a concurrent LR-5 observation is associated with a difference in the probability that LR-3 or LR-4 observations represent hepatocellular carcinoma (HCC) through an individual participant data (IPD) meta-analysis.

METHODS: Multiple databases were searched from 1/2014 to 2/2023 for studies evaluating the diagnostic accuracy of CT/MRI for HCC using LI-RADS v2014/2017/2018. The search strategy, study selection, and data collection process can be found at https://osf.io/rpg8x . Using a generalized linear mixed model (GLMM), IPD were pooled across studies and modeled simultaneously with a one-stage meta-analysis approach to estimate positive predictive value (PPV) of LR-3 and LR-4 observations without and with concurrent LR-5 for the diagnosis of HCC. Risk of bias was assessed using a composite reference standard and Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2).

RESULTS: Twenty-nine studies comprising 2591 observations in 1456 patients (mean age 59 years, 1083 [74%] male) were included. 587/1960 (29.9%) LR-3 observations in 1009 patients had concurrent LR-5. The PPV for LR-3 observations with concurrent LR-5 was not significantly different from the PPV without LR-5 (45.4% vs 37.1%, p = 0.63). 264/631 (41.8%) LR-4 observations in 447 patients had concurrent LR-5. The PPV for LR-4 observations with concurrent LR-5 was not significantly different from LR-4 observations without concurrent LR-5 (88.6% vs 69.5%, p = 0.08). A sensitivity analysis for low-risk of bias studies (n = 9) did not differ from the primary analysis.

CONCLUSION: The presence of concurrent LR-5 was not significantly associated with differences in PPV for HCC in LR-3 or LR-4 observations, supporting the current LI-RADS paradigm, wherein the presence of synchronous LR-5 may not alter the categorization of LR-3 and LR-4 observations.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Abedrabbo N, Lerner E, Lam E, et al. Is concurrent LR-5 associated with a higher rate of hepatocellular carcinoma in LR-3 or LR-4 observations? An individual participant data meta-analysis. Abdom Radiol (NY). 2024. PMID: 39333410. doi:10.1007/s00261-024-04580-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。